Background Tobacco smoking is associated with chronic obstructive pulmonary disease (COPD) in more than 80 % of cases. Our aim was to investigate the effect of sustained-release bupropion (amfebutamone) (SR) in promoting abstinence from smoking in patients with COPD. Methods In a double-blind, randomised, placebo-controlled trial 404 individuals with mild or moderate COPD who smoked 15 or more cigarettes per day, were assigned bupropion SR (150 mg twice daily) or placebo for 12 weeks. All patients received smoking cessation counselling. Study medication was taken for 1 week before patients attempted to stop smoking. The primary efficacy endpoint was the complete and continuous abstinence from smoking from the beginning of week 4 to the end ...
AIMS: The primary aim of this study was to compare the efficacy of smoking cessation treatment using...
Objective. To evaluate efficacy of bupropion sustained-release for smoking cessation compared with p...
The objective of the present study was to test whether confronting smokers with previously undetecte...
Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive pulmonary d...
Background: The observations that smokers with chronic obstructive pulmonary disease (COPD) are at i...
Smoking cessation is the most effective way to reduce the risk of developing chronic obstructive pul...
Background Smoking cessation is the most important treatment for smokers with chronic obstructive pu...
AbstractSmoking cessation is the most effective way to reduce the risk of developing chronic obstruc...
Background: Smoking cessation is the single most effective way of preventing progression of chronic ...
SummaryChronic obstructive pulmonary disease (COPD) is increasing in prevalence, and is predicted to...
The mainstay in smoking cessation is counselling in combination with varenicline, nicotine replaceme...
The advent of bupropion hydrochloride sustained release (Zyban) has heralded a major change in the o...
One hundred million deaths were caused by tobacco in the 20th century, and it is estimated that ther...
Introduction: Limited tobacco dependence treatment resources exist for smoking COPD patients not rea...
AIMS: The primary aim of this study was to compare the efficacy of smoking cessation treatment using...
Objective. To evaluate efficacy of bupropion sustained-release for smoking cessation compared with p...
The objective of the present study was to test whether confronting smokers with previously undetecte...
Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive pulmonary d...
Background: The observations that smokers with chronic obstructive pulmonary disease (COPD) are at i...
Smoking cessation is the most effective way to reduce the risk of developing chronic obstructive pul...
Background Smoking cessation is the most important treatment for smokers with chronic obstructive pu...
AbstractSmoking cessation is the most effective way to reduce the risk of developing chronic obstruc...
Background: Smoking cessation is the single most effective way of preventing progression of chronic ...
SummaryChronic obstructive pulmonary disease (COPD) is increasing in prevalence, and is predicted to...
The mainstay in smoking cessation is counselling in combination with varenicline, nicotine replaceme...
The advent of bupropion hydrochloride sustained release (Zyban) has heralded a major change in the o...
One hundred million deaths were caused by tobacco in the 20th century, and it is estimated that ther...
Introduction: Limited tobacco dependence treatment resources exist for smoking COPD patients not rea...
AIMS: The primary aim of this study was to compare the efficacy of smoking cessation treatment using...
Objective. To evaluate efficacy of bupropion sustained-release for smoking cessation compared with p...
The objective of the present study was to test whether confronting smokers with previously undetecte...